- Home
- ONON vs BBIO Comparison
ONON vs BBIO Comparison
Compare ONON & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONON | BBIO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.7B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ONON | BBIO |
|---|---|---|
| Price | $37.94 | $67.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 25 |
| Target Price | $60.15 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 5.9M | 2.6M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $19.58 | $89.45 |
| Revenue Next Year | $19.98 | $73.78 |
| P/E Ratio | $56.05 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $31.41 | $38.57 |
| 52 Week High | $55.95 | $84.94 |
Technical Indicators
Market Signals| Indicator | ONON | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 49.68 |
| Support Level | $31.52 | $67.57 |
| Resistance Level | $37.89 | $69.85 |
| Average True Range (ATR) | 1.26 | 2.54 |
| MACD | -0.20 | 0.31 |
| Stochastic Oscillator | 36.23 | 57.25 |
Price Performance
Historical ComparisonAbout ONON On Holding AG
Founded in Switzerland in 2010, sportswear firm On Holding generates 93% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.